Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial

B Brittany N. Flores S Seungyoon B. Yu I Isaac V. Cohen M Melania H. Fanok W Wei Luan R Romeo D. Maciuca L Linus D. Sun R Richard M. Tsai M Maurits Vissers L Lars Smits T Tommy M. Bunte A Anna Bakardjiev S Srijana Balasundar M Meredith E. K. Calvert M Marcus Y. Chin S Sarah K. Dobbins W William E. Dowdle M Meng Fang J Jules A. A. C. Heuberger C Connie L. Ha F Fen Huang T Takashi Miyamoto M Maksim Osipov L Lidia Madrid San Martin K Katie Saund D David Tatarakis A Anthony Q. Vu C Chenling Xiong G Gene W. Yeo G Geert Jan Groeneveld L Leonard H. van den Berg S Shyeilla Dhuria A Anthony A. Estrada D Danna Jennings T Thomas Sandmann C Carole Ho K Kimberly Scearce-Levie E Ernie Yulyaningsih A Adam K. Walker G Gilbert Di Paolo L Lesley A. Kane M Matthew D. Troyer (Denali Therapeutics, South San Francisco, CA) J Joseph W. Lewcock